“We are excited to have initiated ENLIGHTEN-Fibrosis, the first of two pivotal Phase 3 trials addressing MASH, and we are on track to begin the ENLIGHTEN-Cirrhosis trial for compensated cirrhotic MASH patients in the second quarter,” stated Rohan Palekar, CEO of 89bio. “Because of its demonstrated anti-fibrotic and metabolic benefits, we believe that pegozafermin has the potential to be the leading therapy in treating advanced MASH patients with fibrosis. We are focused on the execution of our Phase 3 trials for MASH and our synergistic Phase 3 trial in severe hypertriglyceridemia, which we anticipate topline data from in 2025. These key clinical developments, coupled with our agreement for commercial supply, are designed to strategically enhance our readiness for potential commercialization.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
- ‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
- 89bio assumed with a Buy at BofA
- 89bio Enhances Board with Biopharma Veteran Martin Babler
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com